Analysis of a multitude of additional, randomized controlled trials has also revealed an increased stroke incidence compared with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, glitazones or with just insulin (210). This evidence concerns the gene INS and stroke disorder.